Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005850 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 2 study of Depression and Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 20
- Study locations
NCT00005850 is a Phase 2 study of Depression and Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 21 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00005850, a Phase 2 study of Depression and Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue, anxiety and depression which worsen quality of life.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
- DRUG fluoxetine
Study Locations (20)
Florida
- Broward General Medical Center - Fort Lauderdale
- Memorial Regional Hospital Comprehensive Cancer Center - Hollywood
- Florida Hospital Cancer Institute - Orlando
- Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center - West Palm Beach
Illinois
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- West Suburban Center for Cancer Care - River Forest
- Saint Anthony Medical Center - Rockford
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Beth Israel Medical Center - Boston
Missouri
- Ellis Fischel Cancer Center - Columbia - Columbia
- Barnes-Jewish Hospital - St Louis
Alabama
- Northeast Alabama Regional Medical Center - Anniston
California
- Veterans Affairs Medical Center - San Diego - San Diego
District of Columbia
- Veterans Affairs Medical Center - Washington, DC - Washington D.C.
Indiana
- Fort Wayne Medical Oncology and Hematology, Incorporated - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2001-08 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005850
The ClinicalTrials.gov registry entry for NCT00005850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00005850 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00005850 about?
NCT00005850 is a clinical study titled "Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer". This trial is designed to test the efficacy of fluoxetine to improve patient's quality of life during chemotherapy. An innovative application of a selective serotonin reuptake inhibitor may modulate the effects of fatigue, anxiety and depression which worsen quality of life.
What is the current status of trial NCT00005850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2001-08. Estimated completion is 2003-09.
What conditions does trial NCT00005850 study?
This clinical trial studies the following conditions: Depression, Lung Cancer, Fatigue, Anxiety Disorder.
What interventions are being tested in trial NCT00005850?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG), fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00005850?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005850 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.